Protagenic Therapeutics Announces Third Quarter 2021 Results and Business Update
16. November 2021 09:58 ET
|
Protagenic Therapeutics, Inc.
NEW YORK, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (Nasdaq: PTIX) a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders,...
Protagenic Therapeutics to Host Virtual Science Review Wednesday, September 8th at 10 AM ET
30. August 2021 09:15 ET
|
Protagenic Therapeutics, Inc.
Scientific rationale and evidence for PT00114 in the treatment of Depression, Anxiety, PTSD and Addiction to be discussed NEW YORK, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Protagenic...
Protagenic Therapeutics Announces Second Quarter 2021 Results and Provides Business Update
17. August 2021 07:45 ET
|
Protagenic Therapeutics, Inc.
NEW YORK, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (Nasdaq: PTIX) a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders,...
Protagenic Therapeutics Updates Timeline for Commencement of Patient Enrollment for PT00114 Clinical Trial
23. Juli 2021 16:21 ET
|
Protagenic Therapeutics, Inc.
NEW YORK, July 23, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (Nasdaq: PTIX) a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders,...
Protagenic Therapeutics to Host Webinar with Dr. Maurizio Fava for its Lead Molecule PT00114 on Tuesday, July 13th at 10:00 AM ET
06. Juli 2021 06:17 ET
|
Protagenic Therapeutics, Inc.
NEW YORK, July 06, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (Nasdaq: PTIX) a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders,...
Protagenic Therapeutics to Present at the H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference on June 17th
16. Juni 2021 09:15 ET
|
Protagenic Therapeutics, Inc.
NEW YORK , June 16, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (Nasdaq: PTIX) a bioharmaceutical company focused on developing drug product candidates to treat stress-related neurologic...
Protagenic Therapeutics, Inc. Announces Closing of $13.2 Million Public Offering and Uplisting to Nasdaq
29. April 2021 15:06 ET
|
Protagenic Therapeutics, Inc.
New York, April 29, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (NASDAQ:PTIX) ("PTIX" or "Company") today announced the closing of an underwritten public offering of 3,180,000 units at a...
Protagenic Therapeutics, Inc. Announces Nasdaq Uplisting and Pricing of $13.2 Million Public Offering
26. April 2021 20:58 ET
|
Protagenic Therapeutics, Inc.
New York, April 26, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (NASDAQ:PTIX) ("PTIX" or "Company") today announced the pricing of an underwritten public offering of 3,180,000 units at a...
Dr. Maurizio Fava of Massachusetts General Hospital to Serve as Principal Investigator for PT00114 Clinical Trial
16. Dezember 2020 09:15 ET
|
Protagenic Therapeutics, Inc.
Clinical Trials of First-in-Class Peptide to Commence in 1H 2021 NEW YORK, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (OTCQB: PTIX) announced today that Dr. Maurizio Fava,...
Protagenic Therapeutics Completes $2.0 Million Convertible Note Financing
08. September 2020 12:10 ET
|
Protagenic Therapeutics, Inc.
Capital to be Used to Complete IND Filing and Commence Phase I/II Clinical Trial for Lead Clinical Compound PT00114 NEW YORK, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc....